Ovarian Cancer Trial, Recruiting NCT04710797 Sponsor: Sun Yat-sen University Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT04710797
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between 18 and 70 years old.
  • Women who have been diagnosed with a specific type of ovarian cancer called epithelial ovarian cancer, at an early stage (FIGO stage IA–IIA), who either have not yet had treatment or had surgery that was not fully completed.
  • Women whose cancer type and features mean they need follow-up chemotherapy after surgery — this includes certain specific subtypes of ovarian cancer (confirm with trial site for which subtype applies to you).
  • Women who are in generally good physical health and able to carry out daily activities with little or no limitation.
  • Women who have read, understood, and signed a consent form agreeing to take part in the trial.

Who may not be able to join:

  • Women whose ovarian cancer is not of the epithelial type, or whose tumours are classed as "borderline" (not clearly cancerous).
  • Women whose lymph nodes looked suspicious on scans before surgery.
  • Women whose lymph nodes appeared suspicious or enlarged during surgery.
  • Women who have had another serious cancer in the last 5 years (some early-stage or low-risk cancers may be exceptions — confirm with trial site).
  • Women who have already had chemotherapy for ovarian cancer, or radiotherapy to the abdomen or pelvis.
  • Women who have a condition affecting their lymphatic system, including unexplained lymphoedema (swelling caused by fluid build-up).
  • Women who have previously had lymph nodes removed from the area behind the abdomen.
  • Women who have other medical conditions that make surgery unsafe.
  • Women who are pregnant.
  • Women who are unable to give informed consent, follow the trial requirements, or attend regular follow-up appointments.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
31 January 2021
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS(Progression-free survival)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov